Tempus, a genomic sequencing firm driving better medical results, is working to bring targeted cancer treatments more widespread. The firm founded by Eric Lefkofsky is using machine learning to effectively map the treatment decision of each patient to make the pattern for further reference. Recently, the firm made a partnership with the University of Chicago to provide data to its doctors to drive better treatment results. With the deal, the firm would offer molecular sequencing and analysis data of at least 1,000 breast cancer patients to the doctors of the University to get improved patient outcomes.
It was reported that though the breast cancer is considered to be very common, the very less accessible data of disease pattern and treatment results is making a negligible reference for the doctors – a real challenge for them. But, with the latest partnership, the doctors of the University of Chicago would find the benefit of accurate genetic information and can execute targeted and informed decisions. Incidentally, the firm has already made partnerships with the Mayo Clinic, Penn Medicine, the University of Michigan, etc.Eric founded Tempus in 2015 and leads the firm as the Chief Executive Officer. Under his supervision, the firm developed an operating system which would help to fight against cancer. The firm combines data science and technology to derive efficient results in fighting against cancer. With that mission, he set up a highly robotic lab at Tempus.
Eric is the co-founder and Chairman of e-commerce marketplace firm, Groupon. He also co-founded predictive analytics platform, Uptake Technologies. Additionally, Eric set up three more firms namely Mediaocean, Echo Global Logistics, and InnerWorkings. To enhance the communities and its lives, he established a foundation called Lefkofsky Family Foundation in 2006. He completed his graduation from the University of Michigan and also completed his J.D. from the University of Michigan Law School.Follow him on Twitter: https://twitter.com/lefkofsky